Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Pasithea Therapeutics is a biotech company focused on developing innovative treatments for CNS disorders, RASopathies, and cancers. Its pipeline includes next-generation MEK inhibitors, monoclonal antibodies for ALS, and small molecules for schizophrenia. The company emphasizes targeted therapies with improved safety, efficacy, and dosing profiles, leveraging proprietary drug design and strategic collaborations to address high unmet medical needs in neurology and oncology markets.
This description was generated via AI from an annual report. Updated about 1 year ago.